In sum, these results strongly support our hypothesis that concomitant CDK4/6 inhibition effectively prevents the unwanted HSR that contributes to therapeutic failure when treating CRC cells with HSP90 inhibitors. This evidence concerns the gene HSP90AA1 and colorectal carcinoma.